Cingulate Inc. Notes Payable, Current
Cingulate Inc. (CING) had Notes Payable, Current of $5.07 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:NotesPayableCurrent · last filed 2026-08-13
- 2026-06-30: Notes Payable, Current $5.07M.
- 2026-03-31: Notes Payable, Current $6.15M.
- 2025-12-31: Notes Payable, Current $6.30M.
- 2025-09-30: Notes Payable, Current $3.18M.
| Period end | Notes Payable, Current |
|---|---|
| 2026-06-30 | $5.07M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $6.15M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $6.30M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.18M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $5.13M 10-Q · filed 2025-08-19 |
| 2025-03-31 | $4.12M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.53M 10-K · filed 2026-03-18 |
| 2023-12-31 | $3.00M 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.00M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $8.00M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $5.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $5.00M 10-K · filed 2024-04-01 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-14 |
| 2020-12-31 | $500.33K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |